新型大环钆基对比剂gadoquatrane的体外与体内稳定性评估
本研究通过体外解离动力学和大鼠体内骨沉积实验,比较了新型四聚体细胞外钆基对比剂gadoquatrane与已上市大环类对比剂的稳定性。结果显示gadoquatrane在强酸环境中的解离半衰期最长,在人血浆中未观察到钆离子释放,大鼠矿化骨中钆浓度极低。
要点
- gadoquatrane在pH 1.2、37°C条件下的解离半衰期为28.6天,高于所有对照大环类对比剂。
- 在人血浆pH 7.4、37°C孵育15天后,gadoquatrane和gadoterate未释放超过定量下限的钆离子。
- 大鼠注射0.6 mmol Gd/kg后1周,gadoquatrane在股骨矿物质骨中未检出含钆结构(<1 nmol Gd/g)。
核心结论
- gadoquatrane在强酸性环境中对钆离子释放的动力学惰性高于所有已上市大环类对比剂,在人血浆中未释放钆离子,大鼠矿化骨中钆浓度极低,支持其高稳定性。
研究设计与样本
- 体外解离实验(pH 1.2和7.4、37°C)结合大鼠体内单次注射(0.6 mmol Gd/kg,相当于人体剂量0.1 mmol Gd/kg)后1周骨组织钆含量分析,比较gadoquatrane与gadoteridol、gadobutrol、gadoterate、gadopiclenol。
关键影像表现/征象
- 体外羟基磷灰石结合率均<0.02%;大鼠骨髓钆浓度2.3-3.0 nmol Gd/g(三种对比剂范围相当);骺端gadoquatrane和gadobutrol均为1.2 nmol Gd/g,低于gadopiclenol的2.2 nmol Gd/g;骨干分别为0.5、1.0和2.7 nmol Gd/g;gadoquatrane在矿化骨中未检出含钆结构(<1 nmol Gd/g),gadopiclenol在骨皮质下可见薄层钆浓度(IQR 17-38 nmol Gd/g,最大值约80 nmol Gd/g),gadobutrol同层钆浓度较低(IQR 1.2-3.5 nmol Gd/g,最大值约12 nmol Gd/g)。
诊断标准与关键数值
- pH 1.2解离半衰期:gadoquatrane 28.6天(95%CI 28.1-29.1),gadopiclenol 14.2天(95%CI 13.8-14.6),gadoterate 2.7天(95%CI 2.6-2.8),gadobutrol 14.1小时(95%CI 13.1-15.1),gadoteridol 2.2小时(95%CI 2.0-2.4);人血浆pH 7.4孵育15天释放钆离子:gadoquatrane和gadoterate未超过定量下限(LLOQ为总钆的0.01%),gadobutrol 0.12%(95%CI 0.11-0.13),gadopiclenol 0.20%(95%CI 0.19-0.21),gadoteridol 0.20%(95%CI 0.20-0.21)。
临床应用与阅片要点
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Gadoquatrane is a tetrameric extracellular gadolinium-based contrast agent (GBCA) with a T1 relaxivity of 11.8 L/(mmol Gd*s) at 1.41 T in human plasma, which is currently in Phase 3 clinical development. In the current study, the stability of gadoquatrane was assessed in comparison with approved macrocyclic GBCAs in several in vitro and in vivo assays.
MATERIALS AND METHODS: Kinetic inertness, a key determinant of complex stability, was assessed for gadoquatrane, gadoteridol, gadobutrol, gadoterate, and gadopiclenol at equimolar Gd concentrations by measuring the time course of dissociation at pH 1.2 and 37°C using a complexometric assay. Kinetic inertness was also determined in human plasma at pH 7.4 and 37°C using ion exchange chromatography coupled to inductively coupled plasma mass spectrometry (ICP-MS). The binding of gadoquatrane, gadobutrol, and gadopiclenol to synthetic hydroxyapatite, the inorganic component of bone, was investigated in vitro and the Gd content in histological bone slices 1 week after a single injection of these 3 selected GBCAs in rats (0.6 mmol Gd/kg, equivalent to a human dose of 0.1 mmol Gd/kg) was analyzed using laser ablation coupled to ICP-MS.
RESULTS: The dissociation half-lives at pH 1.2 (mean, 95% confidence interval in parenthesis) were 28.6 (28.1, 29.1) days for gadoquatrane, 14.2 (13.8, 14.6) days for gadopiclenol, 2.7 (2.6, 2.8) days for gadoterate, 14.1 (13.1, 15.1) hours for gadobutrol, and 2.2 (2.0, 2.4) hours for gadoteridol. After 15 days of incubation in human plasma at pH 7.4, no released Gd 3+ ions above the lower limit of quantification (LLOQ, 0.01% of total Gd) were observed for gadoquatrane and gadoterate, while for gadobutrol, gadopiclenol and gadoteridol the concentrations of released Gd 3+ ions reached 0.12 (0.11, 0.13)%, 0.20 (0.19, 0.21)%, and 0.20 (0.20, 0.21)%, respectively. The rates of dissociation for gadopiclenol and gadoteridol were similar. For gadoquatrane, gadobutrol, and gadopiclenol, the binding to hydroxyapatite was examined. It was very low (< 0.02% of total Gd) for all 3 GBCAs. The Gd concentration 1 week after the injection of 0.6 mmol Gd/kg of the 3 GBCAs in bone marrow were in a comparable range of 2.3-3.0 nmol Gd/g tissue. In the epiphysis the Gd concentrations for gadoquatrane (1.2 (1.0, 1.4)) and gadobutrol (1.2 (1.0, 1.4)) were lower compared to gadopiclenol (2.2 (1.9, 2.6)). In the diaphysis the respective values were 0.5 (0.4, 0.7) nmol Gd/g, 1.0 (0.8, 1.3) nmol Gd/g, and 2.7 (2.1, 3.5) nmol Gd/g. Elemental imaging of the femur obtained in this in vivo study revealed no Gd containing structures in the mineralized bone for gadoquatrane (< 1 nmol Gd/g). For gadopiclenol, a visible thin layer of Gd concentration (interquartile range [IQR]: 17-38 nmol Gd/g, maximum value ~80 nmol Gd/g) in the subcortical layer of the bone was observed. The same layer contained a lower Gd concentration for gadobutrol (IQR: 1.2-3.5 nmol Gd/g, maximum value ~12 nmol Gd/g).
CONCLUSIONS: The investigations demonstrated that gadoquatrane has the highest kinetic inertness towards release of Gd 3+ ions in strong acidic environment compared to all approved macrocyclic GBCAs. In human plasma at pH 7.4 no release of Gd 3+ ions was observed from gadoquatrane, similar to gadoterate and kinetic inertness was higher than for gadoteridol, gadobutrol and gadopiclenol. The high stability of gadoquatrane was supported by very low Gd concentrations in mineralized bone in an in vivo study in rats.
引用
- Gruendemann S, Frenzel T, Lohrke J, et al. In Vitro and In Vivo Stability Assessment of the Novel, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane. Invest Radiol. 2025. PMID: 40359923. doi:10.1097/RLI.0000000000001195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。